Clicky

NeuBase Therapeutics, Inc.(NBSE)

Description: NeuBase Therapeutics, Inc., a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.


Keywords: Biotechnology Biology Acid Gene Expression Dystrophy DNA Genetic Diseases Huntington's Disease Genetic Disorder Oligonucleotide Nucleic Acids RNA Myotonic Dystrophy Gene Silencing

Home Page: www.neubasetherapeutics.com

NBSE Technical Analysis

350 Technology Drive
Pittsburgh, PA 15219
United States
Phone: 646 450 1790


Officers

Name Title
Dr. Dietrich A. Stephan Ph.D. Founder, CEO & Director
Mr. Todd P. Branning CFO & Sec.
Dr. Curt Bradshaw Ph.D. Chief Scientific Officer
Mr. Alan Scrivner J.D. Gen. Counsel
Ms. Shannon McCarthy Chief People Officer
Dr. Robert J. Zamboni Ph.D. Chief of Preclinical Devel. & Member of Scientific Advisory Board
Dr. Ron Sarkar M.B.A., Ph.D. Sr. VP of Corp. Strategy & Bus. Devel.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.2238
Price-to-Sales TTM: 0
IPO Date: 2007-05-01
Fiscal Year End: September
Full Time Employees: 37
Back to stocks